DK0900200T5 - Farmaceutiske sammensætninger til forebyggelse og behandling af sygdom i centralnervesystemet - Google Patents
Farmaceutiske sammensætninger til forebyggelse og behandling af sygdom i centralnervesystemetInfo
- Publication number
- DK0900200T5 DK0900200T5 DK97921232T DK97921232T DK0900200T5 DK 0900200 T5 DK0900200 T5 DK 0900200T5 DK 97921232 T DK97921232 T DK 97921232T DK 97921232 T DK97921232 T DK 97921232T DK 0900200 T5 DK0900200 T5 DK 0900200T5
- Authority
- DK
- Denmark
- Prior art keywords
- nervous system
- central nervous
- prevention
- treatment
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63176196A | 1996-04-23 | 1996-04-23 | |
PCT/US1997/006398 WO1997040011A1 (fr) | 1996-04-23 | 1997-04-16 | Preparations pharmaceutiques pour la prevention et le traitement de troubles du systeme nerveux central |
Publications (2)
Publication Number | Publication Date |
---|---|
DK0900200T3 DK0900200T3 (da) | 2009-03-30 |
DK0900200T5 true DK0900200T5 (da) | 2010-01-11 |
Family
ID=24532629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK97921232T DK0900200T5 (da) | 1996-04-23 | 1997-04-16 | Farmaceutiske sammensætninger til forebyggelse og behandling af sygdom i centralnervesystemet |
Country Status (12)
Country | Link |
---|---|
US (2) | US6603011B1 (fr) |
EP (2) | EP0900200B9 (fr) |
JP (2) | JP4357001B2 (fr) |
AT (1) | ATE416164T1 (fr) |
AU (1) | AU727976B2 (fr) |
BR (1) | BR9708815B1 (fr) |
CA (1) | CA2252515C (fr) |
DE (1) | DE69739142D1 (fr) |
DK (1) | DK0900200T5 (fr) |
ES (1) | ES2318856T4 (fr) |
PT (1) | PT900200E (fr) |
WO (1) | WO1997040011A1 (fr) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020052497A1 (en) | 2000-03-09 | 2002-05-02 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
US6166048A (en) * | 1999-04-20 | 2000-12-26 | Targacept, Inc. | Pharmaceutical compositions for inhibition of cytokine production and secretion |
US6979695B2 (en) | 1996-04-23 | 2005-12-27 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
EP1068186A2 (fr) * | 1998-04-02 | 2001-01-17 | Targacept, Inc. | Preparations pharmaceutiques et leur modes d'utilisation |
US7790757B2 (en) * | 1998-06-16 | 2010-09-07 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
JP4240815B2 (ja) * | 1998-06-16 | 2009-03-18 | ターガセプト,インコーポレイテッド | アリール置換オレフィンアミンと、コリン受容体アゴニストとしてのアリール置換オレフィンアミンの使用 |
US6232316B1 (en) | 1998-06-16 | 2001-05-15 | Targacept, Inc. | Methods for treatment of CNS disorders |
US20050131034A1 (en) | 1998-06-16 | 2005-06-16 | Caldwell William S. | Compounds capable of activating cholinergic receptors |
US6455734B1 (en) * | 2000-08-09 | 2002-09-24 | Magnesium Diagnostics, Inc. | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states |
AU2005201609B2 (en) * | 1999-04-20 | 2007-10-18 | Targacept, Inc | Pharmaceutical compositions for inhibition of cytokine production and secretion |
US20010031771A1 (en) | 1999-05-24 | 2001-10-18 | Gary Maurice Dull | Pharmaceutical compositions and methods for use |
JP2003501416A (ja) * | 1999-06-07 | 2003-01-14 | ターガセプト,インコーポレイテッド | 医薬組成物およびその使用法 |
AU6497200A (en) * | 1999-07-30 | 2001-02-19 | Vertex Pharmaceuticals Incorporated | Acyclic and cyclic amine derivatives |
AU2001257449A1 (en) * | 2000-05-01 | 2001-11-12 | Targacept, Inc. | Imaging of nicotinic acetylcholine receptor subtypes |
FR2847578A1 (fr) * | 2002-11-21 | 2004-05-28 | Rhodia Chimie Sa | Composes amines porteurs d'au moins un allyle et d'un difluoromethyle et procede utile a leur synthese |
FR2838436A1 (fr) * | 2002-04-16 | 2003-10-17 | Rhodia Chimie Sa | Composes amines porteurs d'au moins un allyle et d'un difluoromethyle et procede utile a leur synthese |
EP1494994A2 (fr) * | 2002-04-16 | 2005-01-12 | Rhodia Chimie | Composes amines porteurs d'au moins un allyle et d'un difluoromethyle et procede utile a leur synthese |
CA2563023C (fr) * | 2004-04-02 | 2012-01-24 | Arterial Remodelling Technologies, Inc. | Ensemble endoprothese a base de polymere |
US7459469B2 (en) | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
UA88792C2 (ru) * | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
TWI389889B (zh) * | 2006-05-09 | 2013-03-21 | Targacept Inc | (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型 |
EP2357174A1 (fr) | 2006-05-09 | 2011-08-17 | AstraZeneca AB | Sels de (2S)-(4E)-N-méthyl-5-[(5-isopropoxy)pyridin-3-yl]-4-pentèn-2-amine |
CL2007002684A1 (es) * | 2006-09-15 | 2008-06-27 | Astrazeneca Ab Targacept Inc | Combinacion que comprende un antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina; composicion farmaceutica que la comprende; kit farmaceutico; y uso para tratar perjuicio cognitivo y/o trastorno psicoticos. |
EP2112923A1 (fr) * | 2007-01-22 | 2009-11-04 | Targacept Inc. | Administration intranasale, buccale ou sublinguale d'analogues de métanicotine |
EP2647373A1 (fr) | 2008-05-12 | 2013-10-09 | Targacept, Inc. | Procédés de prévention du développement d'une rétinopathie par l'administration orale d'exo-s-mecamylamine |
WO2010080757A2 (fr) | 2009-01-07 | 2010-07-15 | Astrazeneca Ab | Combinaisons avec un agoniste alpha-4-bêta-2 nicotinique |
SG185497A1 (en) | 2010-05-20 | 2012-12-28 | Astrazeneca Ab | New process for the preparation of aryl substituted olefinic amines |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4965074A (en) | 1985-03-05 | 1990-10-23 | Ciba-Geigy Corporation | Method of treating memory impairment |
US4684654A (en) * | 1985-08-14 | 1987-08-04 | American Cyanamid Company | 3-heteroalkyl-2,4-quinzaolinediones |
US4927838A (en) * | 1987-07-10 | 1990-05-22 | Hoffman-La Roche Inc. | Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors |
US4788206A (en) * | 1987-07-10 | 1988-11-29 | Hoffmann-La Roche Inc. | Pentadieneamides |
US4786646A (en) * | 1987-07-10 | 1988-11-22 | Hoffmann-La Roche Inc. | Cyclopropylpropenamides |
US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
US5210076A (en) | 1988-09-13 | 1993-05-11 | Berliner David L | Methods of treating Parkinson's disease using melanin |
US5356906A (en) | 1989-10-27 | 1994-10-18 | The Du Pont Merck Pharmaceutical Company | (N-phthalimidoalkyl) piperidines useful as treatments for psychosis |
DE4102289A1 (de) | 1991-01-26 | 1992-07-30 | Bayer Ag | Verfahren zur herstellung von (hetero)arylalk(en/in)-ylaminen und neue (hetero)arylkinylamine |
ES2153360T3 (es) | 1991-05-29 | 2001-03-01 | Abbott Lab | Compuestos de isoxazol e de isotiazol que mejoran las funciones de razonamiento. |
US5212188A (en) | 1992-03-02 | 1993-05-18 | R. J. Reynolds Tabacco Company | Method for treatment of neurodegenerative diseases |
US5242935A (en) | 1992-03-06 | 1993-09-07 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
US5227391A (en) | 1992-04-10 | 1993-07-13 | R. J. Reynolds Tobacco Company | Method for treatment of neurodegenerative diseases |
US5723477A (en) | 1994-11-10 | 1998-03-03 | Sibia Neurosciences, Inc. | Modulators of acetylcholine receptors |
US5616707A (en) * | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
JP3899126B2 (ja) * | 1995-01-06 | 2007-03-28 | ターガセプト,インコーポレイテッド | 中枢神経系疾患の予防及び治療のための医薬組成物 |
US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
US5616716A (en) * | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
-
1997
- 1997-04-16 EP EP97921232A patent/EP0900200B9/fr not_active Expired - Lifetime
- 1997-04-16 PT PT97921232T patent/PT900200E/pt unknown
- 1997-04-16 DK DK97921232T patent/DK0900200T5/da active
- 1997-04-16 AT AT97921232T patent/ATE416164T1/de active
- 1997-04-16 CA CA002252515A patent/CA2252515C/fr not_active Expired - Fee Related
- 1997-04-16 BR BRPI9708815-3A patent/BR9708815B1/pt not_active IP Right Cessation
- 1997-04-16 DE DE69739142T patent/DE69739142D1/de not_active Expired - Lifetime
- 1997-04-16 ES ES97921232T patent/ES2318856T4/es not_active Expired - Lifetime
- 1997-04-16 WO PCT/US1997/006398 patent/WO1997040011A1/fr active IP Right Grant
- 1997-04-16 JP JP53818097A patent/JP4357001B2/ja not_active Expired - Fee Related
- 1997-04-16 EP EP08014695A patent/EP1997806A1/fr not_active Withdrawn
- 1997-04-16 AU AU27332/97A patent/AU727976B2/en not_active Ceased
-
2000
- 2000-08-21 US US09/642,351 patent/US6603011B1/en not_active Expired - Fee Related
-
2001
- 2001-10-09 US US09/973,419 patent/US6555684B2/en not_active Expired - Fee Related
-
2008
- 2008-03-11 JP JP2008060649A patent/JP2008247903A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU727976B2 (en) | 2001-01-04 |
JP2000509041A (ja) | 2000-07-18 |
EP0900200B9 (fr) | 2009-10-21 |
DE69739142D1 (de) | 2009-01-15 |
CA2252515A1 (fr) | 1997-10-30 |
WO1997040011A1 (fr) | 1997-10-30 |
PT900200E (pt) | 2009-02-26 |
CA2252515C (fr) | 2006-11-07 |
EP0900200B1 (fr) | 2008-12-03 |
EP0900200A1 (fr) | 1999-03-10 |
JP2008247903A (ja) | 2008-10-16 |
ES2318856T4 (es) | 2010-03-03 |
BR9708815B1 (pt) | 2009-01-13 |
ATE416164T1 (de) | 2008-12-15 |
ES2318856T3 (es) | 2009-05-01 |
US20020032206A1 (en) | 2002-03-14 |
JP4357001B2 (ja) | 2009-11-04 |
BR9708815A (pt) | 2000-01-04 |
US6555684B2 (en) | 2003-04-29 |
US6603011B1 (en) | 2003-08-05 |
DK0900200T3 (da) | 2009-03-30 |
AU2733297A (en) | 1997-11-12 |
EP1997806A1 (fr) | 2008-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0900200T3 (da) | Farmaceutiske sammensætninger til forebyggelse og behandling af sygdom i centralnervesystemet | |
DE69736441D1 (de) | Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen | |
RU93058531A (ru) | Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ лечения | |
UA27911C2 (uk) | Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну | |
NO20000521D0 (no) | 1-(N-fenylaminoalkyl)-piperazin derivater substituert i posisjon 2 på fenylringen | |
ES2184960T3 (es) | Nuevas pirimidin-4-onas-(5,6)-heteroaril condensadas 2,3 disustituidas. | |
IL192287A0 (en) | Pharmaceutical compositions and methods for use | |
ES502656A0 (es) | Un procedimiento para la preparacion de nuevos derivados de 2-propanol | |
ATE334120T1 (de) | Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems | |
DE69834500D1 (de) | Xanthinderivative zur behandlung von hirnischämie | |
DK505584A (da) | Administrationssaet og farmaceutiske praeparater til anvendelse dertil | |
DE69837322D1 (de) | Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln | |
NO864443D0 (no) | Fremgangsmaate for fremstilling av terapeutisk aktive n-substituerte 3-piperidin- eller 3-pyridin-karboksylsyrederivater. | |
DE69300321D1 (de) | Behandlung neurodegenerativer Erkrankungen. | |
DE3766695D1 (de) | Bizyklische diphosphonat-verbindungen und arzneimittel. | |
ES502654A0 (es) | Un procedimiento para la preparacion de nuevos derivados de 2-propanol | |
ATE239470T1 (de) | Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen | |
ATE151774T1 (de) | Cyclopentanperhydrophenanthren-17-beta-(3-furyl - 3-derivate und pharmazeutische präparate davon, zur behandlung von kardiovaskulär-erkrankungen | |
DE69229436D1 (de) | Verwendung von somatostatinanalogen zur behandlung von melanomen | |
ATE293972T1 (de) | Behandlung von chronischen schmerzen | |
MX19761A (es) | Nuevos compuestos y procedimiento para su obtencion. |